Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Fall;37(3):476-86, 396.
doi: 10.1111/j.1748-720X.2009.00408.x.

Off-label prescribing: a call for heightened professional and government oversight

Rebecca Dresser  1 , Joel Frader
Affiliations

Off-label prescribing: a call for heightened professional and government oversight

Rebecca Dresser et al. J Law Med Ethics. 2009 Fall.

Abstract

Under current U.S. law, physicians may prescribe drugs and devices in situations not covered on the label approved by the Food and Drug Administration. Those supporting this system say that requiring FDA approval for off-label uses would unnecessarily impede the delivery of benefits to patients. Patients do benefit from off-label prescribing that is supported by sound scientific and medical evidence. In the absence of such evidence, however, off-label prescribing can expose patients to risky and ineffective treatments. The medical community and federal authorities should more actively promote patients' interests in receiving beneficial off-label treatments. To exercise responsible self-regulation, members of the medical community must determine whether available evidence justifies specific off-label uses and must promote information-gathering when the evidence is inadequate. Physicians should also discuss with patients the uncertainties accompanying off-label uses. Federal authorities should more closely monitor the effects of off-label prescribing and adopt other measures to reduce harm and enhance benefits produced by off-label prescribing.

PubMed Disclaimer

References

    1. Committee on Drugs, American Academy of Pediatrics Uses of Drugs Not Described in the Package Insert (Off-Label Uses) Pediatrics. 2002;110(1):181–183. See, e.g. - PubMed
    2. National Cancer Institute Understanding the Approval Process for New Cancer Treatments. available at < http://newscenter.cancer.gov/clinicaltrials/learning/approval-process-fo...>(last visited June 23, 2009)
    3. Rayburn WF, Farmer FC. Off-Label Prescribing During Pregnancy. Obstetrics and Gynecology Clinics of North America. 1997;24(3):471–478. - PubMed
    4. Siu LL. Clinical Trials in the Elderly — A Concept Comes of Age. New England Journal of Medicine. 2007;356(15):1575–1576. - PubMed
    1. Radley DC, Finkelstein SN, Stafford RS. Off-Label Prescribing among Office-Based Physicians. Archives of Internal Medicine. 2006;166(9):1021–1026. - PubMed
    1. Shah SS, et al. Off-Label Drug Use in Hospitalized Children. Archives of Pediatric and Adolescent Medicine. 2007;161(3):282–290. - PubMed
    2. Kumar P, et al. Medication Use in the Neonatal Intensive Care Unit: Current Patterns and Off-Label Use of Parenteral Medications. Journal of Pediatrics. 2008;152(3):412–415. See also. - PubMed
    1. Asani N, et al. Innovative Off-Label Medication Use. American Journal of Medical Quality. 2006;21(4):246–254. - PubMed
    1. Schultz William B. FDA Deputy Commissioner for Policy, before the U.S. Senate Committee on Labor and Human Resources. Feb 22, 1996. Statement of. available at < http://www.fda.gov/ola/1996/s1447.html> (last visited June 20, 2009)